Cifenline in the short-term treatment of patients with ventricular premature complexes: A double-blind placebo-controlled study

John B. Kostis, Dwight Davis, Jeffrey Kluger, Keiko Aogaichi, Maria Smith

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To study the efficacy and safety of cifenline (cibenzoline), a new antiarrhythmic agent, we enrolled 46 patients with >700 premature ventricular complexes (VPCs)/24 h in an ambulatory electrocardiography study. During an open-label titration phase, 25 patients showed >75% VPC suppression while receiving 130 mg (15 patients) or 160 mg (10 patients) cifenline twice daily. During a double-blind placebo-controlled phase in 23 of these patients, cifenline was more effective than placebo in controlling VPCs (p < 0.0001) and VPC pairs (p < 0.025). A small (0.01 s) increase in QRS duration was observed (p < 0.05) during cifenline treatment. Adverse experiences included gastrointestinal complaints and dizziness as well as two instances of hypotension and one instance of symptomatic ventricular tachycardia. Cifenline appears to be effective and well tolerated in the treatment of VPCs.

Original languageEnglish (US)
Pages (from-to)88-95
Number of pages8
JournalJournal of Cardiovascular Pharmacology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 1989

Fingerprint

Ventricular Premature Complexes
Placebos
Therapeutics
Ambulatory Electrocardiography
Dizziness
Ventricular Tachycardia
Hypotension
cifenline
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{85573ece5707427fb01129643430fa37,
title = "Cifenline in the short-term treatment of patients with ventricular premature complexes: A double-blind placebo-controlled study",
abstract = "To study the efficacy and safety of cifenline (cibenzoline), a new antiarrhythmic agent, we enrolled 46 patients with >700 premature ventricular complexes (VPCs)/24 h in an ambulatory electrocardiography study. During an open-label titration phase, 25 patients showed >75{\%} VPC suppression while receiving 130 mg (15 patients) or 160 mg (10 patients) cifenline twice daily. During a double-blind placebo-controlled phase in 23 of these patients, cifenline was more effective than placebo in controlling VPCs (p < 0.0001) and VPC pairs (p < 0.025). A small (0.01 s) increase in QRS duration was observed (p < 0.05) during cifenline treatment. Adverse experiences included gastrointestinal complaints and dizziness as well as two instances of hypotension and one instance of symptomatic ventricular tachycardia. Cifenline appears to be effective and well tolerated in the treatment of VPCs.",
author = "Kostis, {John B.} and Dwight Davis and Jeffrey Kluger and Keiko Aogaichi and Maria Smith",
year = "1989",
month = "1",
day = "1",
doi = "10.1097/00005344-198907000-00016",
language = "English (US)",
volume = "14",
pages = "88--95",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Cifenline in the short-term treatment of patients with ventricular premature complexes : A double-blind placebo-controlled study. / Kostis, John B.; Davis, Dwight; Kluger, Jeffrey; Aogaichi, Keiko; Smith, Maria.

In: Journal of Cardiovascular Pharmacology, Vol. 14, No. 1, 01.01.1989, p. 88-95.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cifenline in the short-term treatment of patients with ventricular premature complexes

T2 - A double-blind placebo-controlled study

AU - Kostis, John B.

AU - Davis, Dwight

AU - Kluger, Jeffrey

AU - Aogaichi, Keiko

AU - Smith, Maria

PY - 1989/1/1

Y1 - 1989/1/1

N2 - To study the efficacy and safety of cifenline (cibenzoline), a new antiarrhythmic agent, we enrolled 46 patients with >700 premature ventricular complexes (VPCs)/24 h in an ambulatory electrocardiography study. During an open-label titration phase, 25 patients showed >75% VPC suppression while receiving 130 mg (15 patients) or 160 mg (10 patients) cifenline twice daily. During a double-blind placebo-controlled phase in 23 of these patients, cifenline was more effective than placebo in controlling VPCs (p < 0.0001) and VPC pairs (p < 0.025). A small (0.01 s) increase in QRS duration was observed (p < 0.05) during cifenline treatment. Adverse experiences included gastrointestinal complaints and dizziness as well as two instances of hypotension and one instance of symptomatic ventricular tachycardia. Cifenline appears to be effective and well tolerated in the treatment of VPCs.

AB - To study the efficacy and safety of cifenline (cibenzoline), a new antiarrhythmic agent, we enrolled 46 patients with >700 premature ventricular complexes (VPCs)/24 h in an ambulatory electrocardiography study. During an open-label titration phase, 25 patients showed >75% VPC suppression while receiving 130 mg (15 patients) or 160 mg (10 patients) cifenline twice daily. During a double-blind placebo-controlled phase in 23 of these patients, cifenline was more effective than placebo in controlling VPCs (p < 0.0001) and VPC pairs (p < 0.025). A small (0.01 s) increase in QRS duration was observed (p < 0.05) during cifenline treatment. Adverse experiences included gastrointestinal complaints and dizziness as well as two instances of hypotension and one instance of symptomatic ventricular tachycardia. Cifenline appears to be effective and well tolerated in the treatment of VPCs.

UR - http://www.scopus.com/inward/record.url?scp=0024353050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024353050&partnerID=8YFLogxK

U2 - 10.1097/00005344-198907000-00016

DO - 10.1097/00005344-198907000-00016

M3 - Article

C2 - 2475722

AN - SCOPUS:0024353050

VL - 14

SP - 88

EP - 95

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -